W. Kurt Roth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
W. Kurt Roth has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
E. Seifried
Institute of Transfusion Medicine and Immunohaematology, German Red Cross, Johann Wolfgang Goethe University, Frankfurt, Germany
4 shared publicationsErhard Seifried
4 shared publicationsMarijke Weber
Institute Wiesentheid of the Bavarian Red Cross Wiesentheid, Germany
4 shared publicationsStefan Zeuzem
Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe Universität, D-60590 Frankfurt a. M
3 shared publications- Bernd Kronenberger
Herz-Jesu-Hospital
2 shared publications Christian Drosten
Institute Wiesentheid of the Bavarian Red Cross, Wiesentheid, Germany
2 shared publications
Latest Publications
- 4 August 2005
- Published by Wiley in Vox Sanguinis
- Vol. 89 (2) , 71-76
Evaluation of an automated high‐volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment
Background and Objectives Nucleic acid extraction still harbours the potential for improvements in automation and sensitivity of nucleic acid amplification technology (NAT) testing. This study evaluates the feasibility of a novel automated high‐volume extraction protocol for NAT minipool testing in a blood bank setting.Materials and Methods The chemagic Viral DNA/RNA Kit special for automated purification of viral nucleic acids from 9·6 ml of plasma by using the chemagic Magnetic Separation Module I was investigated. Analytical sensitivity for hepatitis C virus (HCV), human immunodeficiency virus‐1 (HIV‐1), hepatitis B virus (HBV), hepatitis A virus (HAV) and parvovirus B19 (B19) was compared to our present manual procedure that involves virus enrichment by centrifugation.Results Chemagic technology allows automation of the viral DNA/RNA extraction process. Viral nucleic acids were bound directly to magnetic beads from 9·6‐ml minipools. By combining the automated magnetic beads‐based extraction technology with our in‐house TaqMan polymerase chain reaction (PCR) assays, 95% detection limits were 280 IU/ml for HCV, 4955 IU/ml for HIV‐1, 249 IU/ml for HBV, 462 IU/ml for HAV and 460 IU/ml for B19, calculated for an individual donation in a pool of 96 donors. The detection limits of our present method were 460 IU/ml for HCV, 879 IU/ml for HIV‐1, 90 IU/ml for HBV, 203 IU/ml for HAV and 314 IU/ml for B19.Conclusions The 95% detection limits obtained by using the chemagic method were within the regulatory requirements for blood donor screening. The sensitivities detected for HCV, HBV, HAV and B19 were found to be in a range similar to that of the manual purification method. Sensitivity for HIV‐1, however, was found to be inferior for the chemagic method in this study.
- 4 August 2005
- Published by Wiley in Vox Sanguinis
- Vol. 89 (2) , 71-76
Evaluation of an automated high‐volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment
Background and Objectives Nucleic acid extraction still harbours the potential for improvements in automation and sensitivity of nucleic acid amplification technology (NAT) testing. This study evaluates the feasibility of a novel automated high‐volume extraction protocol for NAT minipool testing in a blood bank setting.Materials and Methods The chemagic Viral DNA/RNA Kit special for automated purification of viral nucleic acids from 9·6 ml of plasma by using the chemagic Magnetic Separation Module I was investigated. Analytical sensitivity for hepatitis C virus (HCV), human immunodeficiency virus‐1 (HIV‐1), hepatitis B virus (HBV), hepatitis A virus (HAV) and parvovirus B19 (B19) was compared to our present manual procedure that involves virus enrichment by centrifugation.Results Chemagic technology allows automation of the viral DNA/RNA extraction process. Viral nucleic acids were bound directly to magnetic beads from 9·6‐ml minipools. By combining the automated magnetic beads‐based extraction technology with our in‐house TaqMan polymerase chain reaction (PCR) assays, 95% detection limits were 280 IU/ml for HCV, 4955 IU/ml for HIV‐1, 249 IU/ml for HBV, 462 IU/ml for HAV and 460 IU/ml for B19, calculated for an individual donation in a pool of 96 donors. The detection limits of our present method were 460 IU/ml for HCV, 879 IU/ml for HIV‐1, 90 IU/ml for HBV, 203 IU/ml for HAV and 314 IU/ml for B19.Conclusions The 95% detection limits obtained by using the chemagic method were within the regulatory requirements for blood donor screening. The sensitivities detected for HCV, HBV, HAV and B19 were found to be in a range similar to that of the manual purification method. Sensitivity for HIV‐1, however, was found to be inferior for the chemagic method in this study.
- 31 May 2005
- Published by Wiley in Transfusion
- Vol. 45 (6) , 1040-1042
Yield of hepatitis C virus nucleic acid testing among antibody‐reactive or confirmed‐positive samples
- 31 May 2005
- Published by Wiley in Transfusion
- Vol. 45 (6) , 1040-1042
Yield of hepatitis C virus nucleic acid testing among antibody‐reactive or confirmed‐positive samples
- 17 February 2004
- Published by Wiley in Transfusion
- Vol. 44 (2) , 268-274
High prevalence of GBV‐C/HGV among relatives of GBV‐C/HGV‐positive blood donors in blood recipients and in patients with aplastic anemia
BACKGROUND: The prevalence of GB virus C (GBV‐C)/HGV is high in individuals with parenteral risk factors. The frequency of GBV‐C/HGV in blood donors is significantly lower, however it is still far above other parenterally transmitted viruses like HBV and HCV. Therefore, transmission routes apart from parenteral transmission must be considered.STUDY DESIGN AND METHODS: The purpose of the study was to evaluate the prevalence of GBV‐C/HGV in blood donors and relatives of GBV‐C/HGV‐positive and ‐negative blood donors. Prevalence was also analyzed in aplastic anemia patients. Samples were tested by RT‐PCR and partially by ELISA. Positive isolates were sequenced and phylogenetically analyzed.RESULTS: A total of 5733 blood donors were PCR tested and 90 were positive (1.6%). Of these, 98 relatives could be tested. Viremia was found in 14.3 percent and anti‐E2 in 29.5 percent, whereas only 1.1 percent of the relatives of PCR‐negative donors were viremic and 8.5 percent were anti‐E2 positive. Probable virus transmission could be shown in two couples and in six mother–child pairs by sequencing of isolates indicating horizontal and vertical virus transmission, respectively. Recipients of GBV‐C/HGV RNA‐positive blood products were shown to be infected at a rate of 58 percent (18/31). Aplastic anemia patients were positive at a rate of 32 percent (17/53).CONCLUSION: The high percentage of 14.3 percent of GBV‐C/HGV PCR‐positive relatives of GBV‐C/HGV‐positive blood donors suggests intrafamilial transmission. Sequence analyses revealed vertical and horizontal transmission. Although parenteral transmission is highly efficient for GBV‐C/HGV (58% of recipients of GBV‐C/HGV RNA‐positive blood products and 32% of aplastic anemia patients), it appears that sexual and vertical transmission are the most common transmission routes.
- 17 February 2004
- Published by Wiley in Transfusion
- Vol. 44 (2) , 268-274
High prevalence of GBV‐C/HGV among relatives of GBV‐C/HGV‐positive blood donors in blood recipients and in patients with aplastic anemia
BACKGROUND: The prevalence of GB virus C (GBV‐C)/HGV is high in individuals with parenteral risk factors. The frequency of GBV‐C/HGV in blood donors is significantly lower, however it is still far above other parenterally transmitted viruses like HBV and HCV. Therefore, transmission routes apart from parenteral transmission must be considered.STUDY DESIGN AND METHODS: The purpose of the study was to evaluate the prevalence of GBV‐C/HGV in blood donors and relatives of GBV‐C/HGV‐positive and ‐negative blood donors. Prevalence was also analyzed in aplastic anemia patients. Samples were tested by RT‐PCR and partially by ELISA. Positive isolates were sequenced and phylogenetically analyzed.RESULTS: A total of 5733 blood donors were PCR tested and 90 were positive (1.6%). Of these, 98 relatives could be tested. Viremia was found in 14.3 percent and anti‐E2 in 29.5 percent, whereas only 1.1 percent of the relatives of PCR‐negative donors were viremic and 8.5 percent were anti‐E2 positive. Probable virus transmission could be shown in two couples and in six mother–child pairs by sequencing of isolates indicating horizontal and vertical virus transmission, respectively. Recipients of GBV‐C/HGV RNA‐positive blood products were shown to be infected at a rate of 58 percent (18/31). Aplastic anemia patients were positive at a rate of 32 percent (17/53).CONCLUSION: The high percentage of 14.3 percent of GBV‐C/HGV PCR‐positive relatives of GBV‐C/HGV‐positive blood donors suggests intrafamilial transmission. Sequence analyses revealed vertical and horizontal transmission. Although parenteral transmission is highly efficient for GBV‐C/HGV (58% of recipients of GBV‐C/HGV RNA‐positive blood products and 32% of aplastic anemia patients), it appears that sexual and vertical transmission are the most common transmission routes.
- 1 August 2003
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 30 (4) , 189-193
Bericht vom TSE-Meeting «Safety of Blood Components», Frankfurt/M., 21. März 2003
- 1 August 2003
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 30 (4) , 189-193
Bericht vom TSE-Meeting «Safety of Blood Components», Frankfurt/M., 21. März 2003
- 21 May 2003
- Published by Wiley in Transfusion
- Vol. 43 (6) , 835
Reply
- 1 August 2002
- Published by Wiley in Transfusion Medicine
- Vol. 12 (4) , 255-258
The German experience with NAT
- 1 August 2002
- Published by Wiley in Transfusion Medicine
- Vol. 12 (4) , 255-258
The German experience with NAT
- 24 July 2002
- Published by Wiley in Transfusion
- Vol. 42 (7) , 862-868
Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe
BACKGROUND: HCV and HIV‐1 NAT of all blood donations was initiated at our institutions in January 1997 to reduce the residual risk of transfusion‐transmitted virus infections. The yield of NAT after testing more than 3.6 million donations in central Europe is reported. STUDY DESIGN AND METHODS: Automated pipetting instruments were used to pool up to 96 donor samples including those that were antibody reactive. To compensate for dilution of the individual donor samples by pooling, viruses were enriched from the pools by centrifugation at 48,000 ×g. A commercial PCR (Cobas Amplicor, Roche) and an in‐house PCR were applied for HCV and HIV‐1 amplification, respectively. RESULTS: Six HCV and 2 HIV‐1 PCR confirmed‐positive, antibody‐negative donations (yield, 1 in 600,000 and 1 in 1.8 million, respectively) were identified. Thirty‐nine and 11 multiple‐time donors seroconverted for HCV and HIV, respectively, and look‐back procedures were initiated. Archived samples from preseroconversion donations were thawed and retested by single‐sample PCR and remained negative. The recipients of the blood components were traced and tested. All traced recipients were negative for HCV and HIV antibodies. CONCLUSION: The yield of NAT in central European Red Cross blood donors was less than expected from theoretical calculations for American and German multiple‐time donors. Look‐back procedures for HCV and HIV indicated that no donation given before seroconversion of the donor was missed by minipool PCR. Sensitivity of minipool PCR testing after virus enrichment seems to be sufficiently high to close the diagnostic window almost completely.
- 24 July 2002
- Published by Wiley in Transfusion
- Vol. 42 (7) , 862-868
Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe
BACKGROUND: HCV and HIV‐1 NAT of all blood donations was initiated at our institutions in January 1997 to reduce the residual risk of transfusion‐transmitted virus infections. The yield of NAT after testing more than 3.6 million donations in central Europe is reported. STUDY DESIGN AND METHODS: Automated pipetting instruments were used to pool up to 96 donor samples including those that were antibody reactive. To compensate for dilution of the individual donor samples by pooling, viruses were enriched from the pools by centrifugation at 48,000 ×g. A commercial PCR (Cobas Amplicor, Roche) and an in‐house PCR were applied for HCV and HIV‐1 amplification, respectively. RESULTS: Six HCV and 2 HIV‐1 PCR confirmed‐positive, antibody‐negative donations (yield, 1 in 600,000 and 1 in 1.8 million, respectively) were identified. Thirty‐nine and 11 multiple‐time donors seroconverted for HCV and HIV, respectively, and look‐back procedures were initiated. Archived samples from preseroconversion donations were thawed and retested by single‐sample PCR and remained negative. The recipients of the blood components were traced and tested. All traced recipients were negative for HCV and HIV antibodies. CONCLUSION: The yield of NAT in central European Red Cross blood donors was less than expected from theoretical calculations for American and German multiple‐time donors. Look‐back procedures for HCV and HIV indicated that no donation given before seroconversion of the donor was missed by minipool PCR. Sensitivity of minipool PCR testing after virus enrichment seems to be sufficiently high to close the diagnostic window almost completely.
- 24 July 2002
- Published by Wiley in Transfusion
- Vol. 42 (7) , 869-875
NAT for HBV and anti‐HBc testing increase blood safety
Routine HBV PCR screening of blood donations to our institutes was introduced in January 1997 to complete the NAT screening program for transfusion-relevant viruses. Testing was successively extended to customer transfusion services with a total of 1,300,000 samples tested per year. Minipools of 96 blood donation samples were formed by automatic pipettors. HBsAg-reactive samples were included. HBV particles were enriched from the minipools by centrifugation. Conventional and in-house TaqMan PCRs were successively applied for HBV amplification. Sensitivity reached 1000 genome equivalents per mL for each individual donation. Confirmatory single-sample and single-sample enrichment PCRs were established with sensitivities of 300 and 5 to 10 genome equivalents per mL, respectively. After screening of 3.6 million donor samples, 6 HBV PCR-positive, HBsAg-negative donations were identified. Two samples were from infected donors who had not seroconverted and four were from chronic anti-HBc-positive low-level HBV carriers. Retesting by single-sample PCR of 432 samples confirmed positive for HBsAg identified 37 donations that were negative in minipool PCR. Donor-directed look-back procedures indicated that no infected donor who had not yet seroconverted was missed by minipool PCR. However, recipient-directed look-back procedures revealed two anti-HBc-positive recipients of HBsAg-negative minipool PCR-negative, anti-HBc-positive and single-sample PCR-positive blood components. After testing randomly selected 729 HBsAg-negative minipool PCR-negative, anti-HBc-positive donors by single-sample enrichment PCR, 7 were identified with < or = 10 HBV particles per mL of donor plasma. Minipool PCR testing after virus enrichment was sensitive enough to identify HBsAg-negative donors who had seroconverterd and HBsAg-negative, anti-HBc-positive chronic HBV carriers. HBV NAT in conjunction with anti-HBc screening would reduce the residual risk of transfusion-transmitted HBV infection.
- 24 July 2002
- Published by Wiley in Transfusion
- Vol. 42 (7) , 869-875
NAT for HBV and anti‐HBc testing increase blood safety
Routine HBV PCR screening of blood donations to our institutes was introduced in January 1997 to complete the NAT screening program for transfusion-relevant viruses. Testing was successively extended to customer transfusion services with a total of 1,300,000 samples tested per year. Minipools of 96 blood donation samples were formed by automatic pipettors. HBsAg-reactive samples were included. HBV particles were enriched from the minipools by centrifugation. Conventional and in-house TaqMan PCRs were successively applied for HBV amplification. Sensitivity reached 1000 genome equivalents per mL for each individual donation. Confirmatory single-sample and single-sample enrichment PCRs were established with sensitivities of 300 and 5 to 10 genome equivalents per mL, respectively. After screening of 3.6 million donor samples, 6 HBV PCR-positive, HBsAg-negative donations were identified. Two samples were from infected donors who had not seroconverted and four were from chronic anti-HBc-positive low-level HBV carriers. Retesting by single-sample PCR of 432 samples confirmed positive for HBsAg identified 37 donations that were negative in minipool PCR. Donor-directed look-back procedures indicated that no infected donor who had not yet seroconverted was missed by minipool PCR. However, recipient-directed look-back procedures revealed two anti-HBc-positive recipients of HBsAg-negative minipool PCR-negative, anti-HBc-positive and single-sample PCR-positive blood components. After testing randomly selected 729 HBsAg-negative minipool PCR-negative, anti-HBc-positive donors by single-sample enrichment PCR, 7 were identified with < or = 10 HBV particles per mL of donor plasma. Minipool PCR testing after virus enrichment was sensitive enough to identify HBsAg-negative donors who had seroconverterd and HBsAg-negative, anti-HBc-positive chronic HBV carriers. HBV NAT in conjunction with anti-HBc screening would reduce the residual risk of transfusion-transmitted HBV infection.
- Open Access
- 1 December 2001
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (12) , 4302-4308
TaqMan 5′-Nuclease Human Immunodeficiency Virus Type 1 PCR Assay with Phage-Packaged Competitive Internal Control for High-Throughput Blood Donor Screening
Screening of blood donors for human immunodeficiency virus type 1 (HIV-1) infection by PCR permits the earlier diagnosis of HIV-1 infection compared with that by serologic assays. We have established a high-throughput reverse transcription (RT)-PCR assay based on 5′-nuclease PCR. By in-tube detection of HIV-1 RNA with a fluorogenic probe, the 5′-nuclease PCR technology (TaqMan PCR) eliminates the risk of carryover contamination, a major problem in PCR testing. We outline the development and evaluation of the PCR assay from a technical point of view. A one-step RT-PCR that targets the gag genes of all known HIV-1 group M isolates was developed. An internal control RNA detectable with a heterologous 5′-nuclease probe was derived from the viral target cDNA and was packaged into MS2 coliphages (Armored RNA). Because the RNA was protected against digestion with RNase, it could be spiked into patient plasma to control the complete sample preparation and amplification process. The assay detected 831 HIV-1 type B genome equivalents per ml of native plasma (95% confidence interval [CI], 759 to 936 HIV-1 B genome equivalents per ml) with a ≥95% probability of a positive result, as determined by probit regression analysis. A detection limit of 1,195 genome equivalents per ml of (individual) donor plasma (95% CI, 1,014 to 1,470 genome equivalents per ml of plasma pooled from individuals) was achieved when 96 samples were pooled and enriched by centrifugation. Up to 4,000 plasma samples per PCR run were tested in a 3-month trial period. Although data from the present pilot feasibility study will have to be complemented by a large clinical validation study, the assay is a promising approach to the high-throughput screening of blood donors and is the first noncommercial test for high-throughput screening for HIV-1.
- 1 December 2001
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (12) , 4302-4308
Open AccessTaqMan 5′-Nuclease Human Immunodeficiency Virus Type 1 PCR Assay with Phage-Packaged Competitive Internal Control for High-Throughput Blood Donor Screening
Screening of blood donors for human immunodeficiency virus type 1 (HIV-1) infection by PCR permits the earlier diagnosis of HIV-1 infection compared with that by serologic assays. We have established a high-throughput reverse transcription (RT)-PCR assay based on 5′-nuclease PCR. By in-tube detection of HIV-1 RNA with a fluorogenic probe, the 5′-nuclease PCR technology (TaqMan PCR) eliminates the risk of carryover contamination, a major problem in PCR testing. We outline the development and evaluation of the PCR assay from a technical point of view. A one-step RT-PCR that targets the gag genes of all known HIV-1 group M isolates was developed. An internal control RNA detectable with a heterologous 5′-nuclease probe was derived from the viral target cDNA and was packaged into MS2 coliphages (Armored RNA). Because the RNA was protected against digestion with RNase, it could be spiked into patient plasma to control the complete sample preparation and amplification process. The assay detected 831 HIV-1 type B genome equivalents per ml of native plasma (95% confidence interval [CI], 759 to 936 HIV-1 B genome equivalents per ml) with a ≥95% probability of a positive result, as determined by probit regression analysis. A detection limit of 1,195 genome equivalents per ml of (individual) donor plasma (95% CI, 1,014 to 1,470 genome equivalents per ml of plasma pooled from individuals) was achieved when 96 samples were pooled and enriched by centrifugation. Up to 4,000 plasma samples per PCR run were tested in a 3-month trial period. Although data from the present pilot feasibility study will have to be complemented by a large clinical validation study, the assay is a promising approach to the high-throughput screening of blood donors and is the first noncommercial test for high-throughput screening for HIV-1.
- 1 June 2001
- Published by Wiley in Transfusion
- Vol. 41 (6) , 845-846
Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?
- 1 June 2001
- Published by Wiley in Transfusion
- Vol. 41 (6) , 845-846
Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?